Loading...
A Novel Intralymphatic Nanocarrier-Delivery System for Cisplatin Therapy in Breast Cancer with Improved Tumor Efficacy and Lower Systemic Toxicity In Vivo
Cohen, Mark S. ; Cai, Shuang ; Xie, Yumei ; Forrest, M. Laird
Cohen, Mark S.
Cai, Shuang
Xie, Yumei
Forrest, M. Laird
Citations
Altmetric:
Abstract
Background
A lymphatically delivered nanoconjugate of cisplatin was evaluated in an orthotopic mouse model of locoregionally metastatic breast cancer (LABC) to determine if it can overcome some of the limitations of standard cisplatin therapy such as high systemic toxicity.
Methods
Human breast cancer cells (107 MDA-MB-468LN) were injected into the mammary fat pad of female nu/nu mice. Once tumor volume reached 50 mm3; intravenous cisplatin or subcutaneous hyaluronan-cisplatin [HA-cisplatin] nanoconjugate was given 1/week × 3 at 3.3 mg/kg (platinum basis).
Results
Nanoconjugates co-localized with the tumors after subcutaneous peritumoral injection and demonstrated improved efficacy to intravenous cisplatin. After one month, renal tubular hemorrhage and edema were more prevalent in the intravenous formulation compared to subcutaneous HA-cisplatin nanoconjugates.
Conclusions
This nanocarrier delivery platform focuses drug in the areas where tumor burden is greatest, potentially reducing systemic toxicity, and has future applicability as a neoadjuvant or adjuvant therapy for LABC.
Description
Date
2010-12-01
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier Masson
Collections
Research Projects
Organizational Units
Journal Issue
Keywords
Citation
Cohen, Mark S., Shuang Cai, Yumei Xie, and M. Laird Forrest. "A Novel Intralymphatic Nanocarrier Delivery System for Cisplatin Therapy in Breast Cancer with Improved Tumor Efficacy and Lower Systemic Toxicity in Vivo." The American Journal of Surgery 198.6 (2009): 781-86.